ECM
RUBY

ExodusPoint Capital Management’s Rubius Therapeutics, Inc RUBY Stock Holding History

ExodusPoint Capital Management’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,061
Closed -$9K – 2454
2022
Q2 		$9K Sell
10,061
-8,659
-46% -$14.5K ﹤0.01% 1867
2022
Q1 		$103K Buy
+18,720
New +$119K ﹤0.01% 2004
2021
Q1 		– Sell
-19,924
Closed -$151K – 2752
2020
Q4 		$151K Buy
+19,924
New +$118K ﹤0.01% 1788

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

ExodusPoint Capital Management's RUBY Position: Q3 2022 in Review

ExodusPoint Capital Management sold out of Rubius Therapeutics, Inc (RUBY) in Q3 2022, closing a stake of 10,061 shares — an estimated $9K sold.

ExodusPoint Capital Management first reported a position in RUBY in Q4 2020 and held it in 3 quarters. The position peaked at $151K in Q4 2020. 62 funds tracked by Wall St. Rank hold RUBY as of Q3 2022.

  • ExodusPoint Capital Management reported no remaining Rubius Therapeutics, Inc position as of Q3 2022 after selling out during the quarter.
  • ExodusPoint Capital Management sold 10,061 Rubius Therapeutics, Inc shares in Q3 2022, an estimated $9K.
  • ExodusPoint Capital Management first reported a position in Rubius Therapeutics, Inc in Q4 2020 and held it in 3 quarters.
  • ExodusPoint Capital Management's Rubius Therapeutics, Inc position peaked at $151K in Q4 2020.
  • 62 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q3 2022.

Based on ExodusPoint Capital Management's 13F filing for Q3 2022, filed 10 Nov 2022.